Biotie Therapies - Company Announcement

Biotie's Stock Exchange Releases published in 2011

BIOTIE THERAPIES CORP.     STOCK EXCHANGE ANNOUNCEMENT 8 March 2012 at 9.05 a.m.

Biotie's Stock Exchange Releases published in 2011

The following list includes all Biotie Therapies Corp.'s Stock Exchange Releases
and Stock Exchange Announcements published in 2011.

Stock Exchange Releases, Stock Exchange Announcements and Press Releases
published by Biotie are available on the company's web site at
http://www.biotie.com/en/investors/releases

January

03.01.
Biotie Announces Positive Results from First Two Phase III Studies with
Nalmefene in Alcohol Dependence

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

10.01.
Invitation to the Extraordinary General Meeting of Biotie Therapies Corp.

Biotie and Synosia to Combine to Create a Leading CNS Development Company

11.01.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

12.01.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

13.01.
Share capital increase registered with the trade register

19.01.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

February

01.02.
Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp. held
on 1 February 2011

A listing prospectus concerning listing of new shares in Biotie Therapies Corp.
has been published

02.02.
The acquisition of Synosia Therapeutics Holding AG completed

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

03.02.
New Biotie Therapies Corp. shares and increase in share capital registered with
the trade register

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

04.02.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

07.02.
Amendment to Biotie Therapies Corp. Articles of Association registered

Organizational meeting of the Board of Directors of Biotie Therapies Corp.

Changes in Biotie's Financial Information in 2011

March

11.3.
Biotie raises EUR 27 million from institutional and strategic investors

15.3.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

17.3.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

18.3.
New Biotie shares and increase of share capital registered with the trade
register

22.3.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

25.3.
Biotie Therapies Corp. financial statement release 1 January - 31 December 2010

Biotie's Annual Financial Report and Corporate Governance Statement 2010
published

Biotie's Stock Exchange Releases published in 2010

April

05.04.
Invitation to the Annual General Meeting of Biotie Therapies Corp.

07.04.
Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease

May

06.05.
Resolutions of the Annual General Meeting of Biotie Therapies Corp.

13.5.
Biotie Therapies Corp. interim report 1 January - 31 March 2011

24.5.
Biotie announces topline data from an exploratory phase 2a study with SYN118 in
Parkinson's disease

June

06.06.
Change in the number of votes relating to Biotie Therapies Corp.'s shares

15.6.
Biotie Announces Completion of Phase 3 Program with Nalmefene in Alcohol
Dependence; European Marketing Authorization Application (MAA) expected by the
end of 2011

July

05.07.
Change in the number of votes relating to Biotie Therapies Corp.'s shares

25.7.
Biotie Advances Clinical Program for SYN120 with Imaging Study at Johns Hopkins
Center of Excellence

26.7.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act regarding changes in number of votes

28.7.
Correction to Biotie Therapies Corp. interim report for January - March 2011

August

03.08.
Change in the number of votes relating to Biotie Therapies Corp.'s shares

05.08.
Biotie Therapies Corp. Interim report 1 January - 30 June 2011

September

01.09.
New interim CFO in Biotie

02.09.
Change in the number of votes relating to Biotie Therapies Corp.'s shares

27.9.
Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company
Focused on Central Nervous System Drug Development

October

05.10.
Notice to Biotie shareholders on registration of merger plan and documents
available for review

21.10.
Biotie informed that Merck Serono is returning full global rights for safinamide
to Newron

28.10.
Biotie Terminates the Agreement to Acquire Newron

November

04.11.
Biotie's Financial Information in 2012

Biotie Updates Outlook - Non-cash Impairment Charge for SYN118

Biotie Therapies Corp. Interim report 1 January - 30 September 2011

23.11.
Biotie provides UCB partnership update on SYN118

28.11.
Biotie's loan obligations to Tekes reduced by EUR 2.2 million

December

02.12.
Change in the number of votes relating to Biotie Therapies Corp.'s shares

07.12.
The Board of Directors of Biotie Therapies Corp. Decided on Incentive Plans for
Employees

13.12.
US National Institute on Drug Abuse (NIDA) to Conduct Clinical Study on Biotie's
Nepicastat in Cocaine Dependence

21.12.
Biotie's partner Lundbeck submits European Marketing Authorization Application
for Selincro(TM) (nalmefene)

Turku, March 8, 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail:virve.nurmi@biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease.

The company has a strong and balanced development portfolio with several
innovative small molecule and biological drug candidates at different stages of
clinical development. Biotie's products address diseases with high unmet medical
need and significant market potential.

Partnerships with top-tier pharmaceutical partners are in place for several
programs as well as a strategic collaboration with UCB Pharma S.A. The Marketing
Authorization Application for Biotie's most advanced product, Selincro(TM)
(nalmefene) for alcohol dependence was filed in the EU by our partner H.
Lundbeck A/S and was accepted for review by the European Medicines Agency in
December 2011.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.


[HUG#1592333]